Proteomic and metabolomic features in patients with HCC responding to lenvatinib and anti-PD1 therapy

Proteomic and metabolomic features in patients with HCC responding to lenvatinib and anti-PD1 therapy

Summary: Combination therapy (lenvatinib/programmed death-1 inhibitor) is effective for treating unresectable hepatocellular carcinoma (uHCC). We reveal that responders have better overall and progression-free survival, as well as high tumor mutation burden and special somatic variants. We analyze t...

Full description

Bibliographic Details
Main Authors: Zhong-Chen Li, Jie Wang, He-Bin Liu, Yi-Min Zheng, Jian-Hang Huang, Jia-Bin Cai, Lei Zhang, Xin Liu, Ling Du, Xue-Ting Yang, Xiao-Qiang Chai, Ying-Hua Jiang, Zheng-Gang Ren, Jian Zhou, Jia Fan, De-Cai Yu, Hui-Chuan Sun, Cheng Huang, Feng Liu
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:Cell Reports
Subjects:
CP: Cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124724002055

Internet

http://www.sciencedirect.com/science/article/pii/S2211124724002055

Similar Items